N-Acetyl Semax Amidate

CognitiveModified Semax analog / researchExperimental

Also known as: NASA

N-Acetyl Semax Amidate (also called NASA) is a modified Semax analog. This is Semax carrying two standard medicinal-chemistry modifications: acetylation of the N-terminus and amidation of the C-terminus. Both changes block exopeptidase attack at the chain ends, the usual route of degradation for short peptides, and the added lipophilicity is the stated rationale for intranasal use.

Calculate Dose

For research use only.

Key Facts

CAS
2920938-90-3
Molecular Weight (MW)
855 g/mol
Half-life
—
FDA status
Not Approved
Evidence level
Insufficient Evidence
Human dose established
No
Administration Route
Not established in humans
Frequency
Not established in humans
Last updated
Nov 7, 2026
Reviewed
Nov 7, 2026
Targets
Melanocortin-related CNS pathwaysBDNF (by analogy to Semax)

Vendor price snapshot

Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Oct 2026 and Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.

Vendors listing this peptide
7
Listed offers
8
Median price per mg
$3.20/mg
Typical $2.32–$3.82/mg

Open calculator · Compare vendors

Research summary

N-acetylated, C-amidated Semax analog sold for nootropic research, intended to resist peptidases versus standard Semax. Not FDA-approved.

Research evidence

  • Regulatory review (FDA label)None in reviewed sources
  • Controlled human trialsNone in reviewed sources
  • Early or uncontrolled human studiesNone in reviewed sources
  • Lab & animal studiesNone in reviewed sources
How it works

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

Peptide Library's N-Acetyl Semax Amidate profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

N-Acetyl Semax Amidate dosage: no established human dose

N-acetyl semax amidate has no established human dosage. It is a modified form of semax with an acetyl group and an amide added, and no human study of the modified form has been published or registered. The human doses that exist are for plain semax in Russian stroke studies: 12 mg a day in moderate and 18 mg a day in severe stroke for 5–10 days, and 6,000 mcg a day in two 10-day courses during rehabilitation.

Insufficient Evidence

No established human dosage.

Human clinical evidence: None identified.

Preclinical research: N-acetyl semax amidate is semax with both ends chemically capped, which sellers say makes it longer-acting. That claim and its dose have not been tested in a published human study. The only human doses are for unmodified semax, used in Russian hospital stroke care, and they cannot be assumed to carry over to the modified peptide.

Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.

Dosage evidence summary for N-Acetyl Semax Amidate
Human dosing establishedNo
RouteNot established in humans
Evidence levelInsufficient Evidence
Last reviewed2026-11-07

Preclinical and analog research

Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.

Research-reported dosing for N-Acetyl Semax Amidate, one row per studied regimen
Study / contextPopulationDoseRouteFrequencyDurationOutcome studiedSource
Semax (not the N-acetyl amidated form) — acute hemispheric ischaemic stroke (1997)Clinical trial · Controlled clinical study of an analog: semax, the unmodified parent peptideStudied an analog, not N-Acetyl Semax Amidate itselfAdults in the acute period of ischaemic stroke (n=30, with 80 conventionally treated controls)12 mg a day (moderate stroke) or 18 mg a day (severe stroke) of semaxNot stated in the indexed abstractDaily5 days (moderate) or 10 days (severe)Faster recovery of neurological, especially motor, function reported[Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. Zh Nevrol Psikhiatr Im S S Korsakova. 1997.
Semax (not the N-acetyl amidated form) — rehabilitation after ischaemic stroke (2018)Clinical trial · Controlled clinical study of an analog: semax, the unmodified parent peptideStudied an analog, not N-Acetyl Semax Amidate itselfAdults after ischaemic stroke (n=110, semax and non-semax subgroups)6,000 mcg a day of semaxNot stated in the indexed abstractDailyTwo 10-day courses 20 days apartHigher plasma BDNF levels and better motor and Barthel scores reported[The efficacy of semax in the tretament of patients at different stages of ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2018.

Where sources disagree

  • The modification changes how long the peptide lasts and possibly how strong it is, so a semax dose is not a dose of N-acetyl semax amidate.
  • The semax doses come from acute stroke treatment in hospital. The nootropic uses the modified form is sold for have no trial.

Reconstitution

Common research vial sizes: 10 mg, 20 mg, 30 mg.

Reconstitution arithmetic for N-Acetyl Semax Amidate
VialBacteriostatic waterConcentrationPer 0.01 mL
10 mg2 mL5 mg/mL50 mcg per 0.01 mL
30 mg3 mL10 mg/mL100 mcg per 0.01 mL

These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.

Calculate reconstitution & dose →

Handling & administration

Timing Notes
Educational catalog only — not medical advice

Sequence & molecular data

Sequence and molecular data for N-Acetyl Semax Amidate
Molecular formulaC39H54N10O10S
Molecular weight855 g/mol
CAS number2920938-90-3
AppearanceWhite lyophilized powder
FormulationLyophilized Powder
PubChem CID172638603

Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.

Science

Mechanism of Action

This is Semax carrying two standard medicinal-chemistry modifications: acetylation of the N-terminus and amidation of the C-terminus. Both changes block exopeptidase attack at the chain ends, the usual route of degradation for short peptides, and the added lipophilicity is the stated rationale for intranasal use. The underlying pharmacology is assumed to match Semax — modulation of brain-derived neurotrophic factor expression and of monoamine transmission, without the corticotropic activity of the ACTH parent. Comparative pharmacokinetic data between the modified and unmodified forms has not been published, so claims of greater potency or duration should be treated as unverified.

Origin

Synthetic modified Semax.

Targets

Melanocortin-related CNS pathwaysBDNF (by analogy to Semax)

Regulatory & research status

N-Acetyl Semax Amidate is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

Regulatory and research status for N-Acetyl Semax Amidate
FDA statusNot Approved
AvailabilityResearch-Only
WADA (sport)Unknown / Not Listed
Library classificationResearch-Only

How FDA approval, compounding and research-only status differ

Benefits

Stability-oriented Semax analog research

N-Acetyl Semax Amidate side effects

N-Acetyl Semax Amidate has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.

Side Effects

  • Nasal irritation if used IN
  • Unknown chronic safety

Storage & stability

Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.

Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.

Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.

Read the full guide: how to store peptides before and after reconstitution →

Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.

N-Acetyl Semax Amidate: frequently asked questions

What is N-Acetyl Semax Amidate?

N-acetylated, C-amidated Semax analog sold for nootropic research, intended to resist peptidases versus standard Semax. Not FDA-approved.

How does N-Acetyl Semax Amidate work?

This is Semax carrying two standard medicinal-chemistry modifications: acetylation of the N-terminus and amidation of the C-terminus. Both changes block exopeptidase attack at the chain ends, the usual route of degradation for short peptides, and the added lipophilicity is the stated rationale for intranasal use.

Is N-Acetyl Semax Amidate FDA approved?

No. N-Acetyl Semax Amidate is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

What peptides are similar to N-Acetyl Semax Amidate?

Compounds most often compared with N-Acetyl Semax Amidate include Semax, Adamax, Selank and Cerebrolysin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

References

Related research, comparisons & guides

Related peptides

Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 3

This N-Acetyl Semax Amidate profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error

Track N-Acetyl Semax Amidate research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →